From Shiga toxin-producing Escherichia coli infection to haemolytic uraemic syndrome – bacterial, host and iatrogenic factors in children
Open Access
- 16 April 2026
- journal article
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 22 (1) , 14
Abstract
Background: Shiga toxin-producing Escherichia coli infection is the most common cause of haemolytic uraemic syndrome in children – a form of thrombotic microangiopathy characterised by haemolysis, thrombocytopaenia, and acute kidney injury. In most cases, Shiga toxin-producing Escherichia coli-induced gastroenteritis is self-limiting; however, approximately 5–15% of patients develop haemolytic uraemic syndrome. Methods: Focused narrative review based on PubMed/MEDLINE searches covering the past 20 years, with emphasis on the last 5 years. Results and conclusions: The development of Shiga toxin-producing Escherichia coli and haemolytic uraemic syndrome in children results from gastrointestinal infection with Shiga toxin-producing bacteria, predominantly Escherichia coli, in combination with host susceptibility and modifiable clinical factors. Shiga toxin plays a central role in pathogenesis by binding to the Gb3 receptor and inducing endothelial cell injury, leading to thrombotic microangiopathy. This process is further amplified by the inflammatory response and complement activation. The strongest determinants of severe disease and haemolytic uraemic syndrome development are strains producing Stx2, particularly specific subtypes, which exhibit increased cytotoxicity toward endothelial cells. Virulence factors that promote intestinal colonisation and attaching/effacing injury likely intensify mucosal damage and systemic toxin exposure. The risk of haemolytic uraemic syndrome is higher in younger children, possibly due to increased Gb3 expression and immaturity of mechanisms regulating inflammation and complement activation. Available data also suggest a role for host genetic factors, particularly those related to complement regulation and endothelial function. Potentially modifiable clinical factors include delayed or insufficient hydration, as well as the use of antibiotics, antimotility agents, and nephrotoxic drugs, all of which may increase the risk of haemolytic uraemic syndrome.Keywords
This publication has 110 references indexed in Scilit:
- Evaluation of Hypertension in Pediatric Hemolytic Uremic Syndrome (A Cross‐Sectional Study)Health Science Reports, 2025
- Neutralizing antibodies in the intestinal mucosa are essential to control gastrointestinal infection by Shiga toxin‐producing Escherichia colimLife, 2025
- Neurological involvement in children with hemolytic uremic syndromeEuropean Journal of Pediatrics, 2021
- Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin–Producing Escherichia coliJAMA Pediatrics, 2017
- Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS networkEuropean Journal of Pediatrics, 2015
- Probiotic abilities of riboflavin-overproducing Lactobacillus strains: a novel promising application of probioticsApplied Microbiology and Biotechnology, 2014
- Shiga Toxin Pathogenesis: Kidney Complications and Renal Failure2011
- Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndromeCytometry Part B: Clinical Cytometry, 2004
- Podocyte process effacement in vivoMicroscopy Research and Technique, 2002
- Contractile proteins in podocytes: immunocytochemical localization of actin and alpha-actinin in normal and nephrotic rat kidneysVirchows Archiv B Cell Pathology Including Molecular Pathology, 1991